- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Alcon third-quarter profit increases by 51%
Alcon's quarterly earnings per share came in above analysts' expectations and rose 51% from last year.
Hunenberg, Switzerland-Alcon's quarterly earnings per share came in above analysts' expectations and rose 51% from last year. The company also lowered its revenue guidance, while raising its earnings outlook for the full year 2008.
The reported net income for the third quarter was $627.1 million or $2.07 per share, higher than last year's $415.3 million or $1.38 per share for the third quarter, said the company in a prepared statement. The net earnings for the most recent quarter included a $239.5 million tax benefit associated with losses on the value of the company's investment in and advances to the former Summit Autonomous Inc.
Sales for the quarter rose 14.1% to $1.52 billion from $1.34 billion in the prior-year quarter, while analysts had a revenue consensus of $1.54 billion, according to the company. The acquisition of WaveLight AG contributed 1.4 percentage points of sales growth in the third quarter.
Consumer eye-care sales for the quarter increased 10.5% to $223.7 million. Sales of contact lens disinfectants grew 2.6% and sales of artificial tears products increased 28%, said the company.
